Exchange: NASDAQ·Updated 07:43 PM EDT
HALO logo

HALOHalozyme Therapeutics Inc.

$76.20
$2.42
(3.08%)
Today
Closed $76.20
$0.13
(0.17%)
After Hours
EarningsAug 4
Mkt Cap$9.04B
Vol1.47M
News
all
press releases
Halozyme Appoints David Ramsay as President Drug Delivery
Halozyme Appoints David Ramsay as President Drug Delivery Halozyme Appoints David Ramsay as President Drug Delivery PR Newswire SAN DIEGO, June 30, 2026 SAN DIEGO, June 30, 2026 /PRNewswire/ --Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment...
PR Newswire
News Placeholder
More News
News Placeholder
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
News Placeholder
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on...
PR Newswire
News Placeholder
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Zacks
News Placeholder
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Zacks
News Placeholder
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Zacks
News Placeholder
Company News for May 13, 2026
Companies In The News Are: SPG, HIMS, NOVT, HALO.
Zacks
News Placeholder
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Zacks
<
1
2
...
>

Advertisement|Remove ads.